Supporting Information for

Publication

**4-(2-Methyloxazol-4-yl)benzenesulfonamide**

Anton A. Shetnev1\*, Julia A. Efimova2, Mikhail K. Korsakov1,2, Anél Petzer3, Jacobus P. Petzer3

1 Pharmaceutical Technology Transfer Center, Yaroslavl State Pedagogical University named after K.D.Ushinsky, Yaroslavl, 150000, Russian Federation; a.shetnev@list.ru (A.A.S.); mkkors@mail.ru (M.K.K.)

2 Department of Organic Chemistry, Russian State University named after A. N. Kosygin, Moscow, 115035, Russian Federation; julia.efimova.555@gmail.com (J.A.E.).

3 Pharmaceutical Chemistry and Centre of Excellence for Pharmaceutical Sciences, North-West University, Potchefstroom, 2520, South Africa; 12264954@nwu.ac.za (A.P.); jacques.petzer@nwu.ac.za (J.P.P.)

**\*** Correspondence: a.shetnev@list.ru (A.A.S.)

*Contents:*

|  |  |
| --- | --- |
| Copies of 1H and 13C NMR spectra for compound **1**  |  |
|  |  |
|  |  |

1H and 13C NMR spectra for 4-(2-methyloxazol-4-yl)benzenesulfonamide (**1**)



